0.710
0.00 (0.00%)
| Penutupan Terdahulu | 0.710 |
| Buka | 0.710 |
| Purata Dagangan (3B) | 854 |
| Modal Pasaran | 6,957,672 |
| Harga / Jualan (P/S) | 2.89 |
| Harga / Buku (P/B) | 1.26 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,196.25% |
| EPS Cair (TTM) | -24.46 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 215.50% |
| Nisbah Semasa (MRQ) | 0.070 |
| Aliran Tunai Operasi (OCF TTM) | -15.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 7.57 M |
| Pulangan Atas Aset (ROA TTM) | -68.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -727.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Orgenesis, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company’s business includes two reporting segments: Octomera and Therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 20.14% |
| % Dimiliki oleh Institusi | 0.79% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |